Ventyx Biosciences, Inc. announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system penetrant NLRP3 inhibitor. The Phase 1 trial of VTX3232 is a two-part, randomized, double-blind, placebo-controlled single ascending dose and multiple ascending dose (MAD) trial designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTX3232 in adult healthy volunteers. The trial will explore a broad range of doses and will include serial cerebrospinal fluid (CSF) sampling to assess brain exposure.

Topline results from the trial are expected in the first half of 2024. There is a growing body of preclinical data suggesting NLRP3's role as a central driver of neuroinflammation and thus believe VTX3232 may have therapeutic potential in a range of neuroinflammatory conditions with high unmet medical need, including Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS), among others. In addition to VTX3232, are also evaluating VTX2735, a peripherally restricted NLRP3 inhibitor, in a Phase 2 proof-of-mechanism trial in patients with familial cold autoinflammatory syndrome (FCAS).

FCAS is the most common subset of cryopyrin-associated periodic syndrome, a group of rare autoinflammatory conditions caused by gain-of-function mutations in the NLRP3 gene. Beyond CAPS, believe VTX2735 may have therapeutic potential across a broad range of chronic inflammatory conditions that are characterized by NLRP3-induced excess IL-1ß, including large dermatologic, rheumatic and cardiovascular disease. Upon activation, NLRP3 acts as a ‘danger sensor' in the body, releasing the pro-inflammatory cytokines IL-1ß and IL-18 and inducing uncontrolled, lytic cell death (pyroptosis).

These processes lead to chronic inflammation, thereby implicating NLRP3 in a large number of systemic and neuroinflammatory diseases.